

Ignace Vergote

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6027499/publications.pdf>

Version: 2024-02-01

396
papers

33,748
citations

8172

76
h-index

4641

170
g-index

408
all docs

408
docs citations

408
times ranked

24995
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 943-953. | 13.9 | 2,066 |
| 2 | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164. | 13.9 | 1,860 |
| 3 | Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308. | 0.8 | 1,240 |
| 4 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 852-861. | 5.1 | 1,237 |
| 5 | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428. | 13.9 | 1,176 |
| 6 | Epithelial ovarian cancer. <i>Lancet</i> , The, 2019, 393, 1240-1253. | 6.3 | 1,039 |
| 7 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 12-39. | 1.2 | 859 |
| 8 | Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. <i>Ultrasound in Obstetrics and Gynecology</i> , 2000, 16, 500-505. | 0.9 | 747 |
| 9 | Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 884-889. | 0.8 | 684 |
| 10 | ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705. | 0.6 | 665 |
| 11 | Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment. <i>Journal of Clinical Oncology</i> , 2002, 20, 3396-3403. | 0.8 | 626 |
| 12 | Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. <i>Lancet</i> , The, 2001, 357, 176-182. | 6.3 | 598 |
| 13 | Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 113-125. | 3.0 | 597 |
| 14 | Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329. | 0.8 | 500 |
| 15 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCGI). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423. | 1.2 | 500 |
| 16 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384. | 9.4 | 493 |
| 17 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019, 30, 1080-1087. | 0.6 | 456 |
| 18 | Simple ultrasoundâ€“based rules for the diagnosis of ovarian cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 31, 681-690. | 0.9 | 435 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Logistic Regression Model to Distinguish Between the Benign and Malignant Adnexal Mass Before Surgery: A Multicenter Study by the International Ovarian Tumor Analysis Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 8794-8801. | 0.8 | 396 |
| 20 | A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. <i>Cell Research</i> , 2020, 30, 745-762. | 5.7 | 391 |
| 21 | 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer InterGroup Ovarian Cancer Consensus Conference (GCIG OCCC) Tj ETQq1 1 0.784314 rgB770verlo | 0.7 | 370 |
| 22 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691. | 9.4 | 356 |
| 23 | Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. <i>Gynecologic Oncology</i> , 1998, 71, 431-436. | 0.6 | 355 |
| 24 | Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. <i>BMJ: British Medical Journal</i> , 2010, 341, c6839-c6839. | 2.4 | 336 |
| 25 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370. | 9.4 | 326 |
| 26 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473. | 0.8 | 318 |
| 27 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. <i>Cancer</i> , 2003, 98, 229-238. | 2.0 | 305 |
| 28 | Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 799-808. | 5.1 | 279 |
| 29 | HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. <i>British Journal of Cancer</i> , 2011, 104, 863-870. | 2.9 | 270 |
| 30 | Endometriosis and the development of malignant tumours of the pelvis. A review of literature. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2004, 18, 349-371. | 1.4 | 257 |
| 31 | Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. <i>Lancet Oncology, The</i> , 2010, 11, 646-652. | 5.1 | 228 |
| 32 | Sentinel nodes in vulvar cancer: Long-term follow-up of the GRONingen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. <i>Gynecologic Oncology</i> , 2016, 140, 8-14. | 0.6 | 226 |
| 33 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171. | 9.4 | 221 |
| 34 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 620-631. | 5.1 | 215 |
| 35 | Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 424-437. | 0.7 | 212 |
| 36 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. <i>Annals of Oncology</i> , 2017, 28, 727-732. | 0.6 | 203 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. <i>European Radiology</i> , 2014, 24, 889-901. | 2.3 | 189 |
| 38 | Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687. | 5.1 | 187 |
| 39 | Ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 159-179. | 2.0 | 186 |
| 40 | Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 609-619. | 5.1 | 186 |
| 41 | Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555. | 13.9 | 182 |
| 42 | Management of Borderline Ovarian Neoplasms. <i>Journal of Clinical Oncology</i> , 2007, 25, 2928-2937. | 0.8 | 174 |
| 43 | ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760. | 1.2 | 167 |
| 44 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067. | 7.7 | 157 |
| 45 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239. | 2.0 | 154 |
| 46 | Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 226-234. | 0.9 | 154 |
| 47 | Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (<sc>IOTA</sc>) studies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 9-20. | 0.9 | 153 |
| 48 | Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval >=12 months) subpopulation of OVA-301 phase III randomized trial. <i>Annals of Oncology</i> , 2011, 22, 39-48. | 0.6 | 146 |
| 49 | Advanced epithelial ovarian cancer: 1998 consensus statements. <i>Annals of Oncology</i> , 1999, 10, 87-92. | 0.6 | 146 |
| 50 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628. | 5.8 | 144 |
| 51 | Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131. | 13.9 | 144 |
| 52 | Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454. | 9.4 | 141 |
| 53 | HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015, 7, 108. | 3.6 | 138 |
| 54 | Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018, 29, 1784-1792. | 0.6 | 125 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. <i>Journal of Clinical Oncology</i> , 2016, 34, 2271-2278. | 0.8 | 114 |
| 56 | Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 776-779. | 1.2 | 113 |
| 57 | Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2015, 113, 817-826. | 2.9 | 111 |
| 58 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630. | 0.9 | 111 |
| 59 | Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 448-458. | 5.1 | 110 |
| 60 | Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 15-21. | 0.6 | 107 |
| 61 | Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. <i>European Journal of Cancer</i> , 2011, 47, S88-S92. | 1.3 | 106 |
| 62 | Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. <i>Gynecologic Oncology</i> , 2013, 128, 6-11. | 0.6 | 105 |
| 63 | Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. <i>Stem Cell Reports</i> , 2020, 14, 717-729. | 2.3 | 105 |
| 64 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. <i>Annals of Oncology</i> , 2021, 32, 757-765. | 0.6 | 105 |
| 65 | Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. <i>European Journal of Cancer</i> , 2012, 48, 1649-1656. | 1.3 | 104 |
| 66 | ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190. | 1.4 | 99 |
| 67 | Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. <i>British Journal of Cancer</i> , 2014, 111, 680-688. | 2.9 | 98 |
| 68 | Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 2324-2332. | 1.3 | 97 |
| 69 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353. | 0.3 | 96 |
| 70 | Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. <i>Annals of Oncology</i> , 2000, 11, 281-288. | 0.6 | 95 |
| 71 | Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. <i>European Journal of Cancer</i> , 2017, 83, 88-98. | 1.3 | 93 |
| 72 | Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300. | 0.8 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. <i>Journal of Clinical Oncology</i> , 2006, 24, 4528-4530. | 0.8 | 83 |
| 74 | Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222. | 3.2 | 83 |
| 75 | Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, . | 5.8 | 83 |
| 76 | MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762. | 0.8 | 82 |
| 77 | Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34. | 0.6 | 81 |
| 78 | Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231. | 3.2 | 80 |
| 79 | Timing of debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 11-19. | 1.2 | 79 |
| 80 | Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 22-26. | 1.2 | 78 |
| 81 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675. | 5.8 | 78 |
| 82 | Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1220-1228. | 3.2 | 77 |
| 83 | Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Tj ETQq1 1 0.784314 rgBT /Overlock 1511-1516. | 0.6 | 76 |
| 84 | BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). <i>European Journal of Cancer</i> , 2014, 50, 2090-2098. | 1.3 | 75 |
| 85 | Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002. | 0.8 | 75 |
| 86 | A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 145-152. | 0.6 | 74 |
| 87 | Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. <i>Artificial Intelligence in Medicine</i> , 2003, 28, 281-306. | 3.8 | 71 |
| 88 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895. | 0.9 | 71 |
| 89 | Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 783-787. | 1.3 | 70 |
| 90 | ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121. | 1.3 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111. | 3.6 | 70 |
| 92 | Gynecologic Cancer Intergroup (GCIg) proposals for changes of the current FIGO staging system. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 143, 69-74. | 0.5 | 69 |
| 93 | Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632. | 0.8 | 69 |
| 94 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964. | 1.4 | 68 |
| 95 | Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 862-876. | 5.1 | 68 |
| 96 | Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage lb2-Ilb cervical cancer, EORTC 55994.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5503-5503. | 0.8 | 68 |
| 97 | European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287. | 0.6 | 68 |
| 98 | Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2003, 55, 130-134. | 0.7 | 66 |
| 99 | External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group. <i>Clinical Cancer Research</i> , 2007, 13, 4440-4447. | 3.2 | 65 |
| 100 | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1273. | 2.2 | 65 |
| 101 | Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 18-23. | 0.6 | 64 |
| 102 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. <i>Annals of Oncology</i> , 2006, 17, 200-204. | 0.6 | 63 |
| 103 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234. | 5.8 | 63 |
| 104 | Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 436-440. | 1.2 | 61 |
| 105 | Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 207-211. | 1.1 | 60 |
| 106 | Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENLOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525. | 0.8 | 60 |
| 107 | Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4076-4078. | 0.8 | 59 |
| 108 | Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. <i>Cancer Science</i> , 2012, 103, 1334-1341. | 1.7 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women. <i>European Journal of Cancer</i> , 2002, 38, 57-58. | 1.3 | 58 |
| 110 | Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 4038-4044. | 0.8 | 57 |
| 111 | Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 345-354. | 0.9 | 57 |
| 112 | Clear Cell Carcinoma Compared to Serous Carcinoma in Early Ovarian Cancer: Same Prognosis in a Large Randomized Trial. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 88-93. | 1.2 | 56 |
| 113 | Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. <i>European Journal of Cancer</i> , 2020, 137, 69-80. | 1.3 | 56 |
| 114 | Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. <i>Annals of Oncology</i> , 2003, 14, 1494-1500. | 0.6 | 55 |
| 115 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14. | 0.6 | 55 |
| 116 | PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 694-700. | 0.6 | 54 |
| 117 | Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 186-191. | 0.6 | 54 |
| 118 | Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. <i>BMJ, The</i> , 2020, 370, m2614. | 3.0 | 54 |
| 119 | ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 961-982. | 1.2 | 54 |
| 120 | Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. <i>Annals of Oncology</i> , 2011, 22, 49-58. | 0.6 | 53 |
| 121 | Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110. | 1.3 | 53 |
| 122 | Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582. | 0.6 | 53 |
| 123 | A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1415-1423. | 1.3 | 52 |
| 124 | Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 772-780. | 1.2 | 52 |
| 125 | Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. <i>Gynecologic Oncology</i> , 2015, 139, 118-126. | 0.6 | 52 |
| 126 | Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018, 24, 2312-2318. | 3.2 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264. | 0.6 | 51 |
| 128 | Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. <i>Gynecologic Oncology</i> , 2015, 138, 299-303. | 0.6 | 50 |
| 129 | Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 662-671. | 1.1 | 49 |
| 130 | Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. <i>European Journal of Cancer</i> , 2017, 86, 5-14. | 1.3 | 49 |
| 131 | EORTCâ€™GCG process quality indicators for ovarian cancer surgery. <i>European Journal of Cancer</i> , 2009, 45, 517-526. | 1.3 | 48 |
| 132 | Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584. | 0.6 | 46 |
| 133 | Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortiumâ€™OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 268-275. | 1.2 | 46 |
| 134 | Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 447-451. | 0.6 | 45 |
| 135 | Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic review. <i>Gynecological Surgery</i> , 2016, 13, 115-123. | 0.9 | 45 |
| 136 | Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64. | 1.3 | 45 |
| 137 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5511-5511. | 0.8 | 45 |
| 138 | First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 172-177. | 1.2 | 44 |
| 139 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106. | 1.1 | 44 |
| 140 | Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116. | 2.3 | 44 |
| 141 | The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68. | 0.6 | 44 |
| 142 | Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848. | 0.6 | 43 |
| 143 | Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428. | 0.8 | 42 |
| 144 | Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 150, 31-37. | 0.6 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | <scp>ESGO</scp>/<scp>ISUOG</scp>/<scp>IOTA</scp>/<scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 148-168. | 0.9 | 42 |
| 146 | Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2/IB3. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 723-729. | 1.2 | 40 |
| 147 | A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 23-31. | 0.6 | 40 |
| 148 | Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24. | 0.6 | 39 |
| 149 | European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 3-14. | 1.2 | 39 |
| 150 | European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 476-478. | 1.2 | 38 |
| 151 | Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422. | 0.6 | 38 |
| 152 | Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. <i>Annals of Oncology</i> , 2005, 16, viii13-viii19. | 0.6 | 37 |
| 153 | The â€œLeuvenâ€ dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 106, 354-361. | 0.6 | 37 |
| 154 | Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. <i>Cancer</i> , 2019, 125, 4594-4597. | 2.0 | 37 |
| 155 | Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 29, 496-504. | 0.9 | 36 |
| 156 | A scoring system to differentiate malignant from benign masses in specific ultrasoundâ€based subgroups of adnexal tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 33, 92-101. | 0.9 | 36 |
| 157 | Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 363-368. | 1.2 | 35 |
| 158 | Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. <i>Annals of Oncology</i> , 2013, 24, 350-355. | 0.6 | 35 |
| 159 | Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. <i>European Journal of Cancer</i> , 2016, 65, 185-191. | 1.3 | 35 |
| 160 | A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 258-266. | 1.2 | 35 |
| 161 | Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940. | 3.2 | 35 |
| 162 | Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852. | 0.6 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Interval debulking surgery: An alternative for primary surgical debulking?. <i>Journal of Surgical Oncology</i> , 2000, 19, 49-53. | 1.4 | 33 |
| 164 | Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. <i>British Journal of Cancer</i> , 2004, 90, S11-S14. | 2.9 | 33 |
| 165 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276. | 3.2 | 33 |
| 166 | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2. | 1.0 | 33 |
| 167 | The management of borderline tumours of the ovary. <i>Current Opinion in Oncology</i> , 2006, 18, 488-493. | 1.1 | 32 |
| 168 | A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2420-2428. | 1.1 | 32 |
| 169 | Surgery during chemotherapy and at relapse of ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 3-7. | 0.6 | 32 |
| 170 | Diaphragmatic surgery during primary debulking in 89 patients with stage IIIBâ€“IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 489-496. | 0.6 | 31 |
| 171 | Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. <i>Oncolimmunology</i> , 2016, 5, e1111505. | 2.1 | 31 |
| 172 | A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632. | 3.2 | 31 |
| 173 | Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153. | 3.0 | 31 |
| 174 | Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?. <i>Gynecologic Oncology</i> , 2010, 119, 1-2. | 0.6 | 30 |
| 175 | Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). <i>Gynecologic Oncology</i> , 2021, 163, 237-245. | 0.6 | 30 |
| 176 | Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873. | | 30 |
| 177 | Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. <i>European Journal of Cancer</i> , 2000, 36, 84-85. | 1.3 | 29 |
| 178 | A new prognostic model for FIGO stage 1 epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 607-611. | 0.6 | 29 |
| 179 | Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42. | 0.6 | 29 |
| 180 | Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€“Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225. | 1.3 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368. | 0.8 | 29 |
| 182 | Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584. | 1.1 | 28 |
| 183 | A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 274-282. | 3.4 | 27 |
| 184 | Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. <i>European Journal of Cancer</i> , 2016, 61, 52-60. | 1.3 | 27 |
| 185 | The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 462-463. | 0.3 | 27 |
| 186 | Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 143, 88-100. | 1.3 | 27 |
| 187 | First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)â€”a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. <i>Annals of Oncology</i> , 2012, 23, 2613-2619. | 0.6 | 26 |
| 188 | Concordance Between Tumor and Germline <i>BRCA</i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923. | 3.0 | 26 |
| 189 | Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. <i>Radiology and Oncology</i> , 2016, 50, 197-203. | 0.6 | 26 |
| 190 | An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065. | 3.2 | 26 |
| 191 | The Feasibility of Open Laparoscopy in Gynecologicâ€”Oncologic Patients. <i>Gynecologic Oncology</i> , 1997, 66, 138-140. | 0.6 | 25 |
| 192 | Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4047-4054. | 0.8 | 25 |
| 193 | Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. <i>Journal of Physiotherapy</i> , 2018, 64, 245-254. | 0.7 | 25 |
| 194 | Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study. <i>European Radiology</i> , 2019, 29, 309-318. | 2.3 | 25 |
| 195 | Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review. <i>Journal of Ovarian Research</i> , 2019, 12, 105. | 1.3 | 25 |
| 196 | Combining conventional therapy with immunotherapy: A risky business?. <i>European Journal of Cancer</i> , 2019, 113, 41-44. | 1.3 | 25 |
| 197 | Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6005-6005. | 0.8 | 25 |
| 198 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, . | 0.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353. | 1.3 | 24 |
| 200 | Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590. | 2.3 | 24 |
| 201 | Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251. | 0.6 | 24 |
| 202 | Peripherally-driven myeloid NFκB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609. | | 24 |
| 203 | Role of Surgery in Ovarian Cancer: An Update. <i>Acta Chirurgica Belgica</i> , 2004, 104, 246-256. | 0.2 | 23 |
| 204 | Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. <i>Oncologist</i> , 2008, 13, 410-414. | 1.9 | 23 |
| 205 | Multi-center experience of robot-assisted laparoscopic para-aortic lymphadenectomy for staging of locally advanced cervical carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 895-901. | 1.3 | 23 |
| 206 | Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. <i>Targeted Oncology</i> , 2015, 10, 583-596. | 1.7 | 23 |
| 207 | The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016. | 0.8 | 23 |
| 208 | Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018, 20, 280-288. | 2.3 | 23 |
| 209 | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832. | 1.3 | 23 |
| 210 | Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171. | 1.9 | 23 |
| 211 | Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666. | 0.6 | 23 |
| 212 | Treatment of patients with early epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2003, 15, 452-455. | 1.1 | 22 |
| 213 | Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43. | 0.6 | 22 |
| 214 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697. | 0.6 | 22 |
| 215 | European Network of Gynaecological Oncological Trial Groups™ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1328-1330. | 1.2 | 22 |
| 216 | Morcellation of uterine leiomyomas: a plea for patient triage. <i>Lancet Oncology</i> , The, 2015, 16, 1454-1456. | 5.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708. | 1.1 | 22 |
| 218 | Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 67-74. | 0.5 | 22 |
| 219 | Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study. <i>Cells</i> , 2020, 9, 305. | 1.8 | 22 |
| 220 | A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. <i>European Journal of Cancer</i> , 2014, 50, 2408-2416. | 1.3 | 21 |
| 221 | Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium. <i>Journal of Ovarian Research</i> , 2014, 7, 49. | 1.3 | 21 |
| 222 | Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. <i>Facts, Views & Vision in ObGyn</i> , 2015, 7, 32-41. | 0.5 | 21 |
| 223 | Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 415-417. | 0.6 | 20 |
| 224 | Should we screen for endometrial cancer?. <i>Lancet Oncology</i> , The, 2011, 12, 4-5. | 5.1 | 20 |
| 225 | Expression III: patients'™ expectations and preferences regarding physician-patient relationship and clinical management" results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. <i>Annals of Oncology</i> , 2018, 29, 910-916. | 0.6 | 20 |
| 226 | Mitigation and management strategies for ocular events associated with tisotumab vedotin. <i>Gynecologic Oncology</i> , 2022, 165, 385-392. | 0.6 | 20 |
| 227 | The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , 2013, 8, 1226-1235. | 1.3 | 19 |
| 228 | Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. <i>Gynecologic Oncology</i> , 2015, 138, 278-284. | 0.6 | 19 |
| 229 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756. | 1.8 | 19 |
| 230 | Ovarian cancer in children and adolescents: A rare disease that needs more attention. <i>Maturitas</i> , 2016, 88, 3-8. | 1.0 | 19 |
| 231 | AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016, 17, 643. | 1.2 | 19 |
| 232 | Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 537-560. | 1.9 | 19 |
| 233 | Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX) Tj ETQq1 1 01784314 r88T /Ov | 1.7 | 18 |
| 234 | Report of an Early Stopped Randomized Trial Comparing Cisplatin vs. Cisplatin/Ifosfamide/5-Fluorouracil in Recurrent Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 126-129. | 0.7 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. <i>European Journal of Cancer</i> , 2012, 48, 1332-1340. | 1.3 | 18 |
| 236 | HIF1 α ; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014, 7, 1563. | 1.0 | 18 |
| 237 | Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. <i>British Journal of Radiology</i> , 2016, 89, 20160468. | 1.0 | 18 |
| 238 | Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698. | 1.2 | 18 |
| 239 | A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel. <i>Gynecologic Oncology</i> , 2020, 156, 293-300. | 0.6 | 18 |
| 240 | Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. <i>European Journal of Cancer</i> , 2021, 157, 415-423. | 1.3 | 18 |
| 241 | Neoadjuvant chemotherapy for ovarian cancer. <i>Oncology</i> , 2005, 19, 1615-22; discussion 1623-30. | 0.4 | 18 |
| 242 | The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. , 2015, 3, 57. | | 17 |
| 243 | Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1381-1388. | 1.2 | 17 |
| 244 | A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988. | 3.0 | 17 |
| 245 | Bayesian networks in ovarian cancer diagnosis: potentials and limitations. , 0, , . | | 16 |
| 246 | Ovarian cancer and the immune system. <i>Gynecologic Oncology Reports</i> , 2017, 19, 57-58. | 0.3 | 16 |
| 247 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548. | 0.6 | 15 |
| 248 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129. | 2.9 | 15 |
| 249 | Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients. <i>Cancers</i> , 2021, 13, 2360. | 1.7 | 15 |
| 250 | Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Womenâ€™s Cancers. <i>PLoS ONE</i> , 2015, 10, e0143178. | 1.1 | 14 |
| 251 | Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage Iâ€™II Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1256-1260. | 1.2 | 14 |
| 252 | Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.. Journal of Clinical Oncology, 2019, 37, 2525-2525. | 0.8 | 14 |
| 254 | The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. Anticancer Research, 2016, 36, 5781-5792. | 0.5 | 14 |
| 255 | Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. Gynecologic Oncology, 2022, 165, 14-22. | 0.6 | 14 |
| 256 | A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples. PLoS ONE, 2014, 9, e89262. | 1.1 | 13 |
| 257 | Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427. | 1.1 | 13 |
| 258 | Statistical controversies in clinical research: the importance of importance. Annals of Oncology, 2016, 27, 1185-1189. | 0.6 | 13 |
| 259 | Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. British Journal of Cancer, 2018, 119, 330-338. | 2.9 | 13 |
| 260 | Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Research, 2019, 39, 5953-5962. | 0.5 | 13 |
| 261 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394. | 0.8 | 13 |
| 262 | European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529. | 1.2 | 13 |
| 263 | Cumulative dosage effect of aRAD5111/HMGA2 fusion and RAD5111 loss in a case of pseudo-Meigs' syndrome. Genes Chromosomes and Cancer, 2001, 32, 324-329. | 1.5 | 12 |
| 264 | A possible role of the cytochrome P450c17 α gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetrica Et Gynecologica Scandinavica, 2004, 83, 234-239. | 1.3 | 12 |
| 265 | Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIb. Journal of Clinical Oncology, 2008, 26, 5654-5655. | 0.8 | 12 |
| 266 | Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European Journal of Cancer, 2020, 139, 59-67. | 1.3 | 12 |
| 267 | Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228. | 1.1 | 12 |
| 268 | First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. Journal of Clinical Oncology, 2015, 33, 5537-5537. | 0.8 | 12 |
| 269 | Screening for ovarian carcinoma: not quite there yet. Lancet Oncology, The, 2009, 10, 308-309. | 5.1 | 11 |
| 270 | Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: An analysis of 163 patients. European Journal of Cancer, 2011, 47, 191-198. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patientsâ€”A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380. | 0.6 | 11 |
| 272 | Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147. | 1.2 | 11 |
| 273 | Type of chemotherapy has substantial effects on the immune system in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101076. | 1.7 | 11 |
| 274 | Role of Diaphragmatic Surgery in 69 Patients With Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 481-481. | 1.2 | 11 |
| 275 | In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. <i>Anticancer Research</i> , 2016, 36, 5793-5802. | 0.5 | 11 |
| 276 | Dendritic cell-based immunotherapy in ovarian cancer. <i>Oncolmmunology</i> , 2013, 2, e27059. | 2.1 | 10 |
| 277 | Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1339-1343. | 1.2 | 10 |
| 278 | Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. <i>Breast</i> , 2014, 23, 371-377. | 0.9 | 10 |
| 279 | <i>ABC</i> Variation Affects Myelosuppression, Progressionâ€free Survival and Overall Survival in Paclitaxel/Carboplatinâ€treated Ovarian Cancer Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 277-287. | 1.2 | 10 |
| 280 | miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451. | 1.3 | 10 |
| 281 | The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancerâ€”A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613. | 1.7 | 10 |
| 282 | The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 593-601. | 0.6 | 10 |
| 283 | Using Bayesian neural networks with ARD input selection to detect malignant ovarian masses prior to surgery. <i>Neural Computing and Applications</i> , 2008, 17, 489-500. | 3.2 | 9 |
| 284 | The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 542-551. | 1.2 | 9 |
| 285 | Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. <i>Obstetrics and Gynecology</i> , 2011, 118, 1179-1181. | 1.2 | 9 |
| 286 | The â€œLeuvenâ€paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. <i>Gynecologic Oncology</i> , 2013, 128, 34-37. | 0.6 | 9 |
| 287 | Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. <i>Lancet Oncology</i> , The, 2016, 17, 273-274. | 5.1 | 9 |
| 288 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561. | 1.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIg survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514. | 1.2 | 9 |
| 290 | Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. <i>Gynecologic Oncology</i> , 2021, 162, 694-701. | 0.6 | 9 |
| 291 | Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200. | 1.3 | 9 |
| 292 | Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5058-5058. | 0.8 | 9 |
| 293 | Randomized phase III study comparing paclitaxel-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5517-5517. | 0.8 | 9 |
| 294 | Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5550-5550. | 0.8 | 9 |
| 295 | Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899. | 1.7 | 9 |
| 296 | To the Editor. <i>Gynecologic Oncology</i> , 2001, 83, 166-167. | 0.6 | 8 |
| 297 | Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 524-526. | 1.2 | 8 |
| 298 | The Addition of 4% Oxygen to the CO2 Pneumoperitoneum Does Not Decrease Dramatically Port Site Metastases. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 700-703. | 0.3 | 8 |
| 299 | Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIg study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194. | 0.6 | 8 |
| 300 | Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2020, 159, 811-819. | 0.6 | 8 |
| 301 | Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 466-472. | 1.2 | 8 |
| 302 | Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5503-5503. | 0.8 | 8 |
| 303 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871. | 1.4 | 8 |
| 304 | Using artificial neural networks to predict malignancy of ovarian tumors. , 0, , . | | 7 |
| 305 | Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1505-1510. | 1.2 | 7 |
| 306 | Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258. | 0.6 | 7 |
| 308 | Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824. | 1.2 | 7 |
| 309 | miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573. | 2.3 | 7 |
| 310 | Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses. <i>Gynecologic Oncology</i> , 2021, 161, 845-851. | 0.6 | 7 |
| 311 | ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. <i>Facts, Views & Vision in ObGyn</i> , 2021, 13, 107-130. | 0.5 | 7 |
| 312 | Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545. | 0.6 | 7 |
| 313 | AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results. <i>Journal of Clinical Oncology</i> , 2018, 36, 5518-5518. | 0.8 | 7 |
| 314 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017, 8, 64670-64684. | 0.8 | 7 |
| 315 | Laparoscopy in gynaecologic oncology: a review. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 15-26. | 2.0 | 6 |
| 316 | Novel therapies, including enzastaurin, in the treatment of ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 579-598. | 1.9 | 6 |
| 317 | Combined modality adjuvant therapy for high-risk endometrial cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1029-1030. | 5.1 | 6 |
| 318 | Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487. | 1.1 | 6 |
| 319 | Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513. | 1.3 | 6 |
| 320 | Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for Stage IB2-IB cervical cancer: EORTC55994. , 2019, , . | | 6 |
| 321 | Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1094-1097. | 1.2 | 6 |
| 322 | Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 824-828. | 1.2 | 6 |
| 323 | SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5610-TPS5610. | 0.8 | 6 |
| 324 | Experience with PlasmaJet, a novel energy device, in debulking surgery in 87 patients with advanced-stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over | 0,4 | 5 |
| 326 | Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery. International Journal of Gynecological Cancer, 2018, 28, 721-728. | 1.2 | 5 |
| 327 | Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 842. | 1.6 | 5 |
| 328 | Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 2021, 13, 1076. | 1.7 | 5 |
| 329 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680. | 1.1 | 5 |
| 330 | 18€...Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial. , 2020, , . | | 5 |
| 331 | Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.. Journal of Clinical Oncology, 2015, 33, 5549-5549. | 0.8 | 5 |
| 332 | EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).. Journal of Clinical Oncology, 2015, 33, TPS5605-TPS5605. | 0.8 | 5 |
| 333 | Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).. Journal of Clinical Oncology, 2020, 38, TPS6095-TPS6095. | 0.8 | 5 |
| 334 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110. | 0.8 | 5 |
| 335 | Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry. International Journal of Gynecological Cancer, 2022, 32, 740-745. | 1.2 | 5 |
| 336 | Endocrine treatment and prevention of breast and gynaecological cancers. European Journal of Cancer, 2002, 38, 1-11. | 1.3 | 4 |
| 337 | Controversies in surgery in ovarian cancer " what is its real role?. European Journal of Cancer, Supplement, 2003, 1, 115-125. | 2.2 | 4 |
| 338 | External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. Gynecologic Oncology, 2016, 142, 83-88. | 0.6 | 4 |
| 339 | Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers, 2020, 12, 1115. | 1.7 | 4 |
| 340 | Interval debulking surgery: An alternative for primary surgical debulking?. Journal of Surgical Oncology, 2000, 19, 49-53. | 1.4 | 4 |
| 341 | Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.. Journal of Clinical Oncology, 2015, 33, 5565-5565. | 0.8 | 4 |
| 342 | Prospective study evaluating the effect of impaired tamoxifen metabolism on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.. Journal of Clinical Oncology, 2016, 34, 523-523. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Prognostic factors in stage I ovarian carcinoma. <i>Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België</i> , 2001, 63, 257-71; discussion 272-6. | 0.2 | 4 |
| 344 | Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22. | 0.5 | 4 |
| 345 | Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780. | 1.7 | 4 |
| 346 | Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model. <i>Pharmaceutics</i> , 2022, 14, 687. | 2.0 | 4 |
| 347 | Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 30. | 1.7 | 4 |
| 348 | Improving outcome in the first-line management of advanced ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-28. | 2.2 | 3 |
| 349 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424. | 1.1 | 3 |
| 350 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473. | 1.8 | 3 |
| 351 | European Network of Gynaecological Oncological Trial Groupsâ€™ requirements for trials between academic groups and industry partners â€” a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734. | 1.2 | 3 |
| 352 | Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519. | 1.7 | 3 |
| 353 | Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 257, 95-99. | 0.5 | 3 |
| 354 | Immunotherapy in rare ovarian cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 447-456. | 1.1 | 3 |
| 355 | INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 8.4-8. | 1.2 | 3 |
| 356 | Efficacy and safety of chemotherapy (CT) Â± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5504-5504. | 0.8 | 3 |
| 357 | PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5605-TPS5605. | 0.8 | 3 |
| 358 | Mirvetuximab soravtansine, a folate receptor alpha (FRÎ±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5520-5520. | 0.8 | 3 |
| 359 | Immunological parameters as a new lead in the diagnosis of ovarian cancer. <i>Facts, Views & Vision in ObGyn</i> , 2015, 7, 67-72. | 0.5 | 3 |
| 360 | A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?. <i>Facts, Views & Vision in ObGyn</i> , 2015, 7, 73-8. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865. | 1.7 | 3 |
| 362 | Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760. | 1.2 | 3 |
| 363 | RESPONSE: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1170-1171. | 3.0 | 2 |
| 364 | Chemotherapy for cervical cancer. <i>European Clinics in Obstetrics and Gynaecology</i> , 2005, 1, 143-150. | 0.4 | 2 |
| 365 | Reactive Nodular Fibrous Pseudotumor: Case Report and Review of the Literature. <i>Case Reports in Obstetrics and Gynecology</i> , 2014, 2014, 1-4. | 0.2 | 2 |
| 366 | Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCG study of NCIC CTG, EORTC-GCG, and GEICO.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5502-5502. | 0.8 | 2 |
| 367 | Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11061-11061. | 0.8 | 2 |
| 368 | Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5547-5547. | 0.8 | 2 |
| 369 | Treatment algorithm in patients with ovarian cancer. <i>Facts, Views & Vision in ObGyn</i> , 2020, 12, 227-239. | 0.5 | 2 |
| 370 | Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003173. | 1.2 | 2 |
| 371 | Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5571-5571. | 0.8 | 2 |
| 372 | Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5520-5520. | 0.8 | 2 |
| 373 | Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting. , 2011, , 209-227. | | 1 |
| 374 | Diagnosing adnexal tumours before surgery: a critical appraisal of recent evidence. <i>The Obstetrician and Gynaecologist</i> , 2015, 17, 163-171. | 0.2 | 1 |
| 375 | Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 18-26. | 0.3 | 1 |
| 376 | Observational BGOG Study of the Results of Robot-assisted Laparoscopy in 166 Patients with FIGO 2009 Stage IA1-IB1 Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1920-1926. | 0.3 | 1 |
| 377 | Health concerns in long-term survivors with ovarian cancer: Results of Expression VI—Carolyn meets HANNA—Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCG survey.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12023-12023. | 0.8 | 1 |
| 378 | Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1396-1397. | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048. | 1.2 | 1 |
| 380 | Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2599-2599. | 0.8 | 1 |
| 381 | New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes. <i>Facts, Views & Vision in ObGyn</i> , 2016, 8, 161-167. | 0.5 | 1 |
| 382 | Letter to the Editor. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 396-396. | 1.2 | 0 |
| 383 | Endocrine treatment and prevention of breast and gynaecological cancers. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 1-14. | 2.2 | 0 |
| 384 | Clinicopathologic markers of uterine leiomyosarcoma originating from smooth muscle tumors of low malignancy. <i>European Clinics in Obstetrics and Gynaecology</i> , 2005, 1, 164-170. | 0.4 | 0 |
| 385 | OC152: Prevalence of cancer and optimal cut-off levels for mathematical models to distinguish between benign and malignant adnexal masses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 292-293. | 0.9 | 0 |
| 386 | OP17.01: Prospective comparison of one-step and two-step models for the classification of adnexal masses as benign or malignant. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 368-368. | 0.9 | 0 |
| 387 | OC05.01: Predicting ovarian malignancy if simple rules are not applicable. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 7-7. | 0.9 | 0 |
| 388 | OC23.01: New logistic regression model to predict ovarian malignancy in cases for which simple ultrasound rules are not applicable. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 41-42. | 0.9 | 0 |
| 389 | OC21.02: Selection of women with an ovarian tumor for surgery in specialist centers: a comparison of two triaging protocols. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 39-39. | 0.9 | 0 |
| 390 | OC21.04: A prediction model to distinguish between benign, borderline, stage I invasive, higher stage invasive, and metastatic adnexal tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 40-40. | 0.9 | 0 |
| 391 | Reply: The performance of the risk of ovarian malignancy algorithm. <i>British Journal of Cancer</i> , 2011, 105, 187-188. | 2.9 | 0 |
| 392 | EP877â€¦Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , . | | 0 |
| 393 | An analysis of preoperatively HE4 and CA125 in matched samples of patients (pts) with benign disease and borderline ovarian tumors (BOT) with and without invasive implants (InvImp).. <i>Journal of Clinical Oncology</i> , 2013, 31, e22102-e22102. | 0.8 | 0 |
| 394 | Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5551-5551. | 0.8 | 0 |
| 395 | Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5578-5578. | 0.8 | 0 |
| 396 | First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2521-2521. | 0.8 | 0 |